Apr 07, 2022 7:00am EDT ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders
Mar 24, 2022 7:00am EDT ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit
Mar 22, 2022 7:00am EDT ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer’s Vaccine at the 2022 International AD/PDTM Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Mar 10, 2022 7:00am EST ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
Mar 02, 2022 7:00am EST ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease
Feb 03, 2022 7:00am EST ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board
Jan 27, 2022 7:00am EST ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advisory Board
Jan 18, 2022 7:00am EST ProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board
Jan 07, 2022 7:00am EST ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment